03:13 PM EDT, 05/23/2025 (MT Newswires) -- Liquidia ( LQDA ) said Friday the US Food and Drug Administration approved Yutrepiatm for patients with pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease.

The approval was based on the findings of a phase 3 trial that evaluated the prostacyclin analog's effectiveness in facilitating better exercise ability, according to a statement. The candidate was recorded as safe and well-tolerated.

An argument on a motion filed by United Therapeutics ( UTHR ) for a restraining order and preliminary injunction to block Liquidia ( LQDA ) from launching Yutrepia was held on May 20. The motion is pending in court, the company said.

Shares were up 0.8% after resuming trade following a trade halt.

Price: 15.51, Change: -0.05, Percent Change: -0.32